Menu
Search
|

Menu

Close
X

JiangSu Bicon Pharmaceutical Listed Co 002411.SZ (Shenzhen Stock Exchange)

20.59 CNY
-- (--)
As of Sep 20
chart
Previous Close 20.59
Open --
Volume --
3m Avg Volume 3,232,765
Today’s High --
Today’s Low --
52 Week High 34.82
52 Week Low 20.59
Shares Outstanding (mil) 1,532.28
Market Capitalization (mil) 31,549.73
Forward P/E 36.37
Dividend (Yield %) 0.10 ( 0.49 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, CNY)
FY18
3,800
FY17
5,368
FY16
3,724
FY15
2,023
EPS (CNY)
FY18
0.281
FY17
0.583
FY16
0.673
FY15
0.624
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
36.37
32.14
Price to Sales (TTM)
vs sector
4.24
6.55
Price to Book (MRQ)
vs sector
3.32
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
74.82
14.15
LT Debt to Equity (MRQ)
vs sector
62.56
11.31
Return on Investment (TTM)
vs sector
5.61
12.83
Return on Equity (TTM)
vs sector
9.56
14.95

EXECUTIVE LEADERSHIP

Xingfu Xiang
President, Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
Wen Dong
Finance Director, Since 2018
Salary: --
Bonus: --
Bing Chen
Vice President, Secretary of the Board, Since 2016
Salary: --
Bonus: --
Jun Guo
Vice President, Since 2016
Salary: --
Bonus: --
Yudong He
Vice President, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

North Building of Financial Bure
No.18, Zhongwu South Road, Xinyi
XUZHOU   JNG   221400

Phone: +86516.88602411
Site:

JiangSu Bicon Pharmaceutical Listed Company, formerly Jiangsu Jiujiujiu Technology Co., LTD., is a China-based company principally engaged in the research and development, manufacture and distribution of medical products, new energy materials and drug intermediates. The Company operates its businesses through three segments. The Pharmaceuticals segment provides circulatory system, digestive system, respiratory system, nervous system and ophthalmic products. The New Materials segment mainly consists of lithium hexafluorophosphate, high-strength and high modulus polyethylene fibers and others. The Pharmaceutical Intermediates segment consists of 7-ADCA, benzaldehyde, 5.5-dimethylhydantion and trichloropyridine. The Company distributes its products mainly in domestic market.

SPONSORED STORIES